COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP - Sorbonne Université
Article Dans Une Revue Blood Advances Année : 2021

COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP

Alessandro Busca
Alba Cabirta
Roberta Di Blasi
Remy Dulery
Francesca Farina
Barbora Weinbergerová
Josip Batinić
Anna Nordlander
Alberto Lopez-Garcia
Lubos Drgona
Ildefonso Espigado
Iker Falces-Romero
Ramon Garcia-Sanz
Carolina Garcia-Vidal
Anna Guidetti
Nina Khanna
Austin Kulesekararaj
Johan Maertens
Martin Hoenigl
Nikolai Klimko
Philipp Koehler
Antonio Pagliuca
Francesco Passamonti
Oliver Cornely
Livio Pagano
Ambu Gmbh
  • Fonction : Auteur
Astellas Pharma
  • Fonction : Auteur

Résumé

Patients receiving chimeric antigen receptor T cells (CAR-T cells) therapy may be particularly susceptible to coronavirus disease 2019 (COVID-19) because of several factors including the immunosuppression associated to the underlying disease and delayed cytopenias. Regrettably, data on outcomes of CART recipients with COVID-19 are extremely scarce. The aim of this study was to investigate the characteristics and outcomes of COVID-19 in patients treated with CART therapy. The European Hematology Association-Scientific Working Group Infection in Hematology endorsed a survey to collect and analyze data from patients developing COVID-19 after CART therapy. Overall, 459 patients treated with CART cells were reported from 18 European centers. The prevalence of COVID-19 cases was 4.8%. Median time from CART therapy and COVID-19 diagnosis was 169 days. Severe infection occurred in 66.7% of patients and 43.3% of the subjects required admission to ICU. The COVID-19 mortality was 33%. In multivariable analysis, the disease status at the time of COVID-19 trended marginally towards adverse outcome (P=0.075). In conclusion, we documented a high fatality rate for CART patients with COVID-19, supporting the need to design successful interventions to mitigate the risk of infection in this vulnerable group of patients.
Fichier principal
Vignette du fichier
bloodadvances.2021005616.pdf (1.28 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-03430350 , version 1 (16-11-2021)

Identifiants

Citer

Alessandro Busca, Jon Salmanton-García, Paolo Corradini, Francesco Marchesi, Alba Cabirta, et al.. COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP. Blood Advances, 2021, ⟨10.1182/bloodadvances.2021005616/1833925/bloodadvances.2021005616.pdf⟩. ⟨hal-03430350⟩
44 Consultations
175 Téléchargements

Altmetric

Partager

More